Fangchao Zheng

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3660042/publications.pdf

Version: 2024-02-01

1307594 888059 17 492 17 7 citations g-index h-index papers 17 17 17 671 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Updated efficacy of adjuvant epirubicin plusÂcyclophosphamide followed byÂtaxanes versus carboplatin plusÂtaxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up. Breast Cancer Research and Treatment, 2022, 191, 97-105.	2.5	6
2	Durable Disease-free Survival in a Patient with Metastatic Triple-negative Breast Cancer Treated with Olaparib Monotherapy. Current Cancer Drug Targets, 2022, 22, 530-536.	1.6	4
3	Expression and clinical prognostic value of m6A RNA methylation modification in breast cancer. Biomarker Research, 2021, 9, 28.	6.8	13
4	The emerging role of RNA N6-methyladenosine methylation in breast cancer. Biomarker Research, 2021, 9, 39.	6.8	22
5	The intra-tumor heterogeneity of ER and HER2 expression in patients with ER-positive and HER2-positive breast cancer Journal of Clinical Oncology, 2021, 39, e12550-e12550.	1.6	1
6	Meta-Analysis of HER2-Enriched Subtype Predicting the Pathological Complete Response Within HER2-Positive Breast Cancer in Patients Who Received Neoadjuvant Treatment. Frontiers in Oncology, 2021, 11, 632357.	2.8	14
7	Predicting the Efficacy of 5-Fluorouracil–Based Adjuvant Chemotherapy in Gastric Cancer by Microsatellite Instability: A Meta-Analysis. Journal of Environmental Pathology, Toxicology and Oncology, 2019, 38, 21-28.	1.2	4
8	A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis. BMC Cancer, 2019, 19, 1125.	2.6	15
9	Novel fluoropyrimidine-based chemotherapy for advanced well-differentiated neuroendocrine tumors: a clinical update. Expert Opinion on Pharmacotherapy, 2018, 19, 795-807.	1.8	1
10	Clinicopathological Characteristics and Prognoses of Elderly Gastric Cancer Patients after RO Resection: A Multicenter Study in China. Journal of Environmental Pathology, Toxicology and Oncology, 2018, 37, 81-91.	1.2	4
11	Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. Journal of Hematology and Oncology, 2018, 11, 120.	17.0	333
12	Is It a Protective Factor of Helicobacter pylori Infection in Overall Survival of All Gastric Cancer? Evidence from Meta-Analysis. Journal of Environmental Pathology, Toxicology and Oncology, 2017, 36, 309-320.	1.2	6
13	Relationship between Topoisomerase II Alpha Overexpression and Prognosis in Chinese Gastric Cancer Patients. Journal of Environmental Pathology, Toxicology and Oncology, 2017, 36, 207-216.	1.2	2
14	Impact of High Altitude on Clinicopathological Features and Prognosis after RO Resection for Gastric Cancer: A Population-Based Multicenter Study. Journal of Environmental Pathology, Toxicology and Oncology, 2017, 36, 1-14.	1.2	1
15	Clinicopathological Differences and Prognostic Value of Hypoxia-Inducible Factor-2α Expression for Gastric Cancer. Medicine (United States), 2016, 95, e2871.	1.0	3
16	Cardia and Non-Cardia Gastric Cancer Have Similar Stage-for-Stage Prognoses After RO Resection: a Large-Scale, Multicenter Study in China. Journal of Gastrointestinal Surgery, 2016, 20, 700-707.	1.7	19
17	The emerging role of hypoxia-inducible factor-2 involved in chemo/radioresistance in solid tumors. Cancer Treatment Reviews, 2015, 41, 623-633.	7.7	44